The FDA's application record carries an action on BLA 761216, Yusimry (adalimumab-aqvh), sponsored by Emerge Bioscience Pte Ltd. This is a supplement to an already licensed biosimilar - not a new approval, and not a safety communication.
What the record does not say is what the supplement covers. Supplements range from a manufacturing site change to a new presentation to a labelling revision, and those mean very different things to a prescriber. Until the label itself is updated, the honest statement is that an application action occurred and its content is not yet public.
For an Indian gastroenterologist the practical point is narrower. Adalimumab biosimilars are already in routine use here for Crohn's disease and ulcerative colitis, and prescribing follows CDSCO-approved products rather than a US application. This particular product's Indian regulatory position is not stated in the record and should not be assumed.
- Do not change adalimumab prescribing on an application action with no published label change
- Check the FDA label directly before quoting any new indication or presentation to a patient
- Biosimilar interchangeability is a separate regulatory status from licensure - confirm which is being claimed
- In India, prescribe from CDSCO-approved adalimumab products, whose status this record does not address
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free